Drugs / High-titer anti-influenza plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02572817 | Nov 2015 → Apr 2018 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-titer anti-influenza plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02572817 ↗ |
| Route | Intravenous | “Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.” NCT02572817 ↗ |